Tackling unmet needs: new compounds in development for non-functioning pituitary adenomas and rare endocrine diseases

In today’s podcast, we highlight a new company dedicated to the rare endocrine disease world.  Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.

Last week Dr. Blevins and I caught up with Abe Ceesay, Tiburio CEO and Nerissa Kreher M.D., Chief Medical Officer, both highly experienced professionals in the rare endocrine space. We had a fascinating talk about their plans in this area of extensive need for patients. Here’s our talk.

 

© 2020, Pituitary World News. All rights reserved.

LEAVE A REPLY

Please enter your comment!
Please enter your name here